Author

Tom Lloyd

Observed names: T L Lloyd, T.L Lloyd

Institution: Pfizer (United States)

Observed institutions: Pfizer (United States), Bristol-Myers Squibb (United States)

OpenAlex ID: A5110193774

Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.

1996 · S M Witherspoon, D L Emerson, et al. · PubMed · 67

Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens

1991 · N C James, K H Donn, et al. · Antimicrobial Agents and Chemotherapy · 30

Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations

2003 · G Shi, T.L Lloyd, et al. · Journal of Pharmaceutical and Biomedical Analysis · 15

Effect of Alosetron (a New 5‐HT3Receptor Antagonist) on the Pharmacokinetics of Haloperidol in Schizophrenic Patients

1995 · Samir K. Gupta, Robert L. Kunka, et al. · The Journal of Clinical Pharmacology · 15

Trace LC/MS/MS quantitation of 17β‐estradiol as a biomarker for selective estrogen receptor modulator activity in the rat brain

2009 · Chris Petucci, Tom Lloyd, et al. · Journal of Mass Spectrometry · 14

Works count: 5

Citation count: 141

H-index: 5

I10-index: 5